Ulcerative Colitis Market 2016 Pipeline Review of 108 Companies

USA - English

• India - English

PUNE, India, May 30, 2016 /PRNewswire/ --

LifeScienceIndustryResearch.com adds "Ulcerative Colitis - Pipeline Review, H1 2016" market research report with comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects.

Complete report on H1 2016 pipeline review of Ulcerative Colitis with 109 market data tables and 15 figures, spread across 260 pages is available at http://www.lifescienceindustryresearch.com/ulcerative-colitis-pipeline-review-h1-2016.html .

The report also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies discussed in this Ulcerative Colitis Pipeline Review, H1 2016 report include 4D Pharma Plc, AbbVie Inc., Advinus Therapeutics Ltd., Ajinomoto Pharmaceuticals Co., Ltd., Am-Pharma B.V., Amgen Inc., Arena Pharmaceuticals, Inc., Atlantic Healthcare Plc, Avaxia Biologics, Inc., BioAtla, LLC, Bionovis SA, Celgene Corporation, Cellceutix Corporation, ChemoCentryx, Inc., ChironWells GmbH, Chong Kun Dang Pharmaceutical Corp., Coherus BioSciences, Inc., Cosmo Pharmaceuticals S.p.A, Dr. Falk Pharma GmbH, Effimune S.A., Eli Lilly and Company, Enceladus Pharmaceuticals BV, enGene, Inc, Enterome Bioscience SA, Epirus Biopharmaceuticals, Inc., Flexion Therapeutics, Inc., Genentech, Inc., Genor BioPharma Co., Ltd., Gilead Sciences, Inc., GlaxoSmithKline Plc, GW Pharmaceuticals Plc, iCo Therapeutics Inc., Idera Pharmaceuticals, Inc., InDex Pharmaceuticals AB, Innovate Biopharmaceuticals, Inc., INOXIA Lifesciences GmbH, Intas Pharmaceuticals Ltd., Invion Limited, Johnson & Johnson, Kaken Pharmaceutical Co., Ltd., Kymab Limited, Kyowa Hakko Kirin Co., Ltd., LIPID THERAPEUTICS GmbH, Mabion SA, Medestea Research & Production S.p.A., Mitsubishi Tanabe Pharma Corporation, Momenta Pharmaceuticals, Inc., Morphotek, Inc., Mycenax Biotech Inc., Oncobiologics, Inc., Pfizer Inc., Pluristem Therapeutics Inc., ProtAb Ltd, Protagonist Therapeutics Inc., Qu Biologics Inc., Re-Pharm Limited, Rebiotix Inc., Sandoz International GmbH, Seres Therapeutics, Inc., Sigmoid Pharma Limited, Stelic Institute & Co., Inc., sterna biologicals Gmbh & Co KG, Synergy Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Therapeutic Proteins International, LLC, Therapix Biosciences Ltd, Theravance Biopharma, Inc., Tillotts Pharma AG, Trino Therapeutics Limited and Ventria Bioscience.

Drug Profiles discussed in this research are ABS-11, adalimumab biosimilar, AKP-11, amiselimod hydrochloride, Anatabine, Antisense RNAi Oligonucleotide to Inhibit microRNA-214 for Ulcerative Colitis and Colon Cancer, AVX-470, AW/EPO-002, AW/EPO-003, AW/EPOPD-01, AW/EPOPD-02, AW/EPOPD-06, brilacidin tetrahydrochloride, CCX-507, CKD-506, D-9030, dolcanatide, Drug to Inhibit Calpain-2 for Crohn's Diseases and Ulcerative Colitis, EFFI-7H, EG-10, EG-12, enalaprilat, golimumab biosimilar, GSK-2982772, hyaluronate sodium, IAC VITA, IMO-9200, infliximab biosimilar, INN-108, INV-88, KANAb-071, kPPF-1, KY-1006, lipidated tacrolimus, Monoclonal Antibodies to Antagonize Metallothioneins for Ulcerative Colitis and Crohn's Disease, NRG-4, ozanimod hydrochloride, P-Dex, PH-44, PH-46A, PH-5, PNQ-201, Prozumab, PTG-100, ranibizumab biosimilar, RBX-2660, RBX-8225, Recombinant Human Alkaline Phosphatase Replacement for Ulcerative Colitis, Acute Renal Failure, Sepsis and Hypophosphatasia, Rosburix, SER-287, SER-301, Small Molecule to Agonize S1PR1 for Ulcerative Colitis, Small Molecule to Scavenge Nitric Oxide Radical for Ulcerative Colitis and Inflammation, Small Molecules to Inhibit IL-13 for Ulcerative Colitis, Stem Cell Therapy for Inflammatory Bowel Disease, TAK-114, TD-1473, TOP-1288, TP-10 and VEN-120.

Order a copy of Ulcerative Colitis - Pipeline Review, H1 2016 market research report @ http://www.lifescienceindustryresearch.com/purchase?rname=113853 .

Another newly published market research report titled on Enterocolitis - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Enterocolitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterocolitis and special features on late-stage and discontinued projects. Companies discussed in this research are Angothera GmbH, AvidBiotics Corp., Infant Bacterial Therapeutics AB and Sigma-Tau Pharmaceuticals, Inc. Enterocolitis Pipeline market research report of 43 pages is available at http://www.lifescienceindustryresearch.com/enterocolitis-pipeline-review-h1-2016.html .

Explore more reports on Pharmaceuticals.

About Us:   

Life Science Industry Research brings to you to the latest reports in market research on Biotechnology, Diagnostics, Healthcare, Medical Devices and Pharmaceuticals segments from leading research publishers across the globe. These reports also cover data and information on sub-segments and sectors under these life sciences categories.

Connect with Us:  

G+ / Google Plus: https://plus.google.com/112612135957880308475/about

Twitter: https://twitter.com/LifeSciReports

RSS / Feeds: http://www.lifescienceindustryresearch.com/feed

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel: +1-888-391-5441
[email protected]

SOURCE Life Science Industry Research